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Available online 9 October 2015Abstract Background: Myocardial infarction (MI) is deﬁned as myocardial cell necrosis due to
signiﬁcant and sustained ischemia. TN-C is an extracellular matrix glycoprotein that is expressed
in several important steps during the very early stage of cardiogenesis. TN-C is not normally
expressed in the adult heart, but transiently appears during pathological conditions and plays
important roles in tissue remodeling.
Aim: To study the role of TN-C in myocardial infarction patients and to evaluate its role as a
predictor of HF in these patients.
Methods: This study was conducted on 45 cases uniformly divided into 3 closely matched (in age
and sex) groups as follows: Group (I) includes 15 patients who were suffering from AMI; Group
(II) includes 15 patients who were suffering from HF on top of MI; and Group (III) includes 15
healthy volunteers coming for regular annual checkup. 3–6 ml venous blood was collected on the
day of admission under complete aseptic conditions and stored at 70 C until assayed by ELISA.
Results: TN-C levels in the sera of patients with AMI Group (I) were signiﬁcantly higher than those
of healthy volunteers.Moreover, inGroup I ofAMI, a positive correlation betweenTN-C level on one
side and CK, CK-MB and troponin T level on the other side was found. TN-C levels in the sera of
patients with congestive heart failure on top of acute MI Group (II) were signiﬁcantly higher than
those of healthy volunteers. Pro-BNP levels in patients with heart failure Group (II) were signiﬁcantly
higher than those with AMI not complicated with heart failure Group (I). Levels of pro-BNP were
also positively correlated with those of TN-C in patients with heart failure on top of AMI Group (II).
Conclusions: Serum TN-C might be a novel marker reﬂecting active structural remodeling in the
myocardium following infarction, with high TN-C levels at acute stages possibly predicting
progression of LV remodeling. Also, the incorporation of a combination of serum TN-C and plasma
BNP levels may improve risk stratiﬁcation for congestive heart failure after AMI. Further studies on
large scale are needed for more evaluation of TN-C role in HF.
 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
228 R. Gaber et al.1. Introduction
Myocardial infarction (MI) is deﬁned as myocardial cell
necrosis due to signiﬁcant and sustained ischemia.1
TN-C is an extracellular matrix glycoprotein that is
expressed in several important steps during the very early stage
of cardiogenesis. At ﬁrst TN-C is expressed by precardiac
mesodermal cells, when they differentiate into cardiomyocytes.
Once the cells become differentiated and express sarcomeric
proteins, they stop expressing TN-C.2
In normal adult heart, TN-C is not detected in the myocar-
dium except at the chorda tendineae of papillary muscles. But it
appears under pathophysiologic conditions during tissue
remodeling.3 TN-C loosens the attachment of cardiomyocytes
to connective tissues and upregulates expression and activity
of matrix metalloproteinases4 promoting degradation of
connective tissue and contributing to LV dilation. Furthermore,
TN-C could be also a key regulator in early step of ﬁbrosis, and
its elevation may suggest active progression of the ﬁbrosis5.
Ventricular remodeling is accompanied by changes of the
extracellular matrix, and that several molecules related matrix
turnover such as matrix metalloproteinases, and their tissue
inhibitors, carboxy-terminal telopeptide of type I collagen,
amino-terminal propeptide of types I and III procollagen have
received much attention as signiﬁcant biomarkers in HF. TN-C
may be a novel candidate for marker of extracellular matrix
remodeling.6
TN-C has many biologic effects, including regulation of cell
activity during early stage tissue repair.7 It up-regulates MMP
expression in a number of cell types,8 and inhibits strong
linkages between cardiomyocytes and connective tissue.9
Therefore excessive amount of TN-C might cause dispro-
portionate MMP activation, which would lead to progressive
degradation of connective tissues and slippage of myocytes
within the left ventricular wall, ﬁnally resulting in left
ventricular wall thinning and dilatation.10
On the other hand, TN-C has the potential to promote
myocardial repair and prevent ventricular dilatation by
recruitment of myoﬁbroblasts and enhancement of collagen
ﬁbers contraction. Thus the effects of TN-C on ventricular
remodeling are not simple but rather bidirectional.11
The levels of TN-C and its relationship with heart function
in patients with ischemic heart disease were unclear, and the
prognostic value of TN-C in ischemic cardiomyopathy has
not been fully investigated.
The aim of this work was to study the role of serum TN-C
in myocardial infarction patients to evaluate its role as a
predictor of HF in these patients.2. Methods
This study was conducted in on 45 cases uniformly divided
into 3 closely matched (in age and sex) groups as follows:
Group (I) includes 15 patients who were suffering from
AMI; and Group (II) includes 15 patients who were suffering
from HF diagnosed clinically and EF% of heart failure group
was 43 ± 6.
Evaluation done in 1st 24 h after MI.
Group (III) includes 15 healthy volunteers coming for
regular annual checkup.Patients presented with HF due to other causes than MI,
chronic renal failure, chronic liver diseases, endocrinal,
autoimmune diseases, infection, inﬂammatory diseases,
malignant cancer, severe trauma, surgical intervention within
three months were excluded from this study.
 All participants have been subjected for the following:
A. Full clinical examination.
B. ECG and Echo-cardiography.
C. Routine laboratory investigations:
(1) Complete blood picture (CBC).
(2) Cardiac markers (CK, CKMB and Troponin-T): CK, CKMB by spectrophotometric method
(measured in ng/ml).12
 Troponin-T by spectrophotometric method
(measured in pg/ml).13(3) Liver function tests (AST and ALT)
(4) Speciﬁc laboratory investigations
Pro-BNP: ELISA (measured in pg/ml).14
Tenascin-C: ELISA (measured in pg/ml).15
 Sample
6 ml venous blood was collected on the day of admission
under complete aseptic conditions and divided as follows:
3 ml was delivered into plain tube, left for 20 min for coag-
ulation, and centrifuged for 30 min and serum was separated.
Aliquots of serum were delivered into Eppendorf tubes. Serum
samples have been used for evaluation of cardiac markers (CK,
CKMB and Troponin-T), liver function tests (AST and ALT),
and CRP.
– Serum samples for TN-C and pro-BNP were stored at
70 C until assayed by ELISA.
– 2 ml was delivered into tubes containing EDTA for
complete blood picture.
ELISA for Determination of TN-C15
A commercial kit manufactured by Glory Science Company
(USA).
3. Statistics
Data are presented as means ± SD. (S) is statistically
signiﬁcant difference. P was calculated by one way ANOVA
test followed by Turkey’s post-hoc test. P was considered
signiﬁcant at <0.05.
4. Results
Demographic, clinical and echocardiographic data of Groups I
and II are summarized in Table 1.
The mean value of serum level of TN-C in patients having
myocardial infarction of Group (I) was 115.8 ± 49.26 pg/ml
which differed statistically from that of control Group (III)
which was 52.79 ± 5.325 pg/ml. Also, the mean value of serum
level of TN-C in CHF patients of Group (II) 84.47
± 31.09 pg/ml differed signiﬁcantly from that of control
Group (III). C-reactive protein, liver enzymes and cardiac
markers values summarized in Tables 2a–2c. There was
signiﬁcant difference between the mean values of serum level
of TN-C in Group (I) (115.8 ± 49.26) pg/ml and those of
Group (II) (84.47 ± 31.09) pg/ml (Table 3).
Table 1 Demographic, clinical and echocardiographic parameters of HF group and MI without HF group.
HF patients MI without failure patients p Value
Age (years) 52.86 ± 8.50 55.66 ± 8.11 0.34
Gender Male 11 9 0.69
Total cholesterol (mg/dl) 270 ± 18.5 245 ± 20.8 0.37
LDL-C mg/dl 124.0 ± 25.3 118 ± 13.8 0.83
Triglycerides mg/dl 142.2 ± 15.9 136.8 ± 12.67 0.79
Diabetic cases 9 5 0.07
Hypertension 11 7 0.06
BMI 29 ± 3.1 27 ± 2.4 0.61
Smoking 7 8 0.35
Serum creatinine 1.0 ± 0.6 0.8 ± 0.4 0.78
EF% 43 ± 6 65 ± 7 0.02
E/A ratio 0.74 ± 0.12 1.2 ± 0.24 0.099
Anterior MI 10 7 0.13
Inferior MI and others 5 8 0.134
Successful revascularization 3 12 <0.001
P Value < .05 is signiﬁcant and P value > .05 is non signiﬁcant.
Table 2c Cardiac markers in different groups under the study.
Data are presented as means ± SD. P value is considered signiﬁcant if less than 0.05.
Table 2a C-Reactive protein (CRP) in groups under study.
Table 2b Liver enzymes in groups under study.
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Table 3 TN-C levels (pg/ml) and pro-BNP levels (pg/ml) in groups under study.
P1 comparison between Groups I and III.
P2 comparison between Groups II and III.
P3 comparison between Groups I and II.
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ing myocardial infarction of Group (I) was 3131 ± 1024 pg/ml
which differed statistically from that of control Group (III)
which was 45.87 ± 12.52 pg/ml. Also, the mean value of serum
level of pro-BNP in CHF patients of Group (II) 14863
± 8393 pg/ml differed signiﬁcantly from that of control
Group (III). Also, there was signiﬁcant difference between
the mean values of serum level of pro-BNP in Group (I)
(3131 ± 1024) and those of Group (II) (14863 ± 8393 pg/ml)
(Table 3).
Correlation between serum BNP and TN-C levels, and
cardiac markers among different groups in our study was
calculated by linear correlation method. It was found that
there was high signiﬁcant positive correlation between serum
BNP and TN-C levels in Groups (I) and (II) of this study
(Tables 4 and 5, Figs. 1a and b and 2a–c).
For evaluating the role of measuring TN-C level for
predicting the incidence of heart failure among patients with
AMI, the receiver operator characteristics of the values
obtained in this current study for patients with AMI and heartTable 5 Correlation between serum Tenascin-C and the other
cardiac markers.
P< 0.05 was considered signiﬁcant. Values highlighted in bold
indicate signiﬁcant results.
Table 4 Correlation between serum Tenascin-C and pro-BNP
levels in different groups of the study.
P< 0.05 was considered signiﬁcant. Values highlighted in bold
indicate signiﬁcant results.failure were calculated and ROC curve was constructed. The
cutoff value that gave the closest values for sensitivity and
speciﬁcity was 82.95 pg/ml which gives 80% for sensitivity
and 66.67 for speciﬁcity (Tables 6 and 7, Fig. 3).Figure 1 (a and b): Correlation between BNP and TN-C levels in
study groups.
Figure 2 (a–c): Correlation between serum TN-C levels and other cardiac markers in Group (I).
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Advances in diagnostic technology, including new biomarkers
and imaging methods that are more speciﬁc and/or sensitive,
have enabled the detection of even minor myocardial cell
necrosis. These advances called for a re-evaluation of the case
deﬁnition of MI.16The present study measured the TN-C levels in the sera of
patients with AMI without heart failure (Group I), MI
patients complicated by heart failure (Group II) and healthy
volunteers (Group III). TN-C levels in the sera of patients with
AMI (Group I) and patients with congestive heart failure on
top of acute myocardial infarction (Group II) were signiﬁ-
cantly higher than those of healthy volunteers.
Table 6 ROC of Tenascin-C as a predictor of heart failure
after AMI.
At cutoﬀ Sensitivity Speciﬁcity
82.95 80.0% 66.67
Table 7 AUC and ROC curve values for TN-C as a predictor
of emergence of heart failure among patients with AMI.
Area under the curve (AUC) 0.7844
Std. error 0.08531
95% conﬁdence interval 0.6172–0.9517
P value 0.007965
Receiver Operating Characteristic; (ROC) curves for TN-C levels.
Area under the curve (AUC) values were in general interpreted as
0.5–0.6 = poor; 0.6–0.7 = fair; 0.7–0.8 =medium; 0.8–0.9 = good;
0.9–1.0 = excellent.
Figure 3 ROC of TN-C as a predictor of heart failure after
AMI.
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TN-C levels were high in patients with myocardial infarction
and successful revascularization treatment of patients was
associated with decrease in TN-C levels. In the same year, Sato
et al.18 noted signiﬁcantly elevated TN-C levels within 24 h
after onset. Levels peaked at day 5 and then gradually
decreased, reﬂecting local expression in the myocardium. They
stated that this time course of serum TN-C levels corresponds
to local expression of TN-C in infarcted myocardium of
rats and humans as detected by immunohistochemistry.
Recently Yang et al.,19 studied the correlation between
serum TN-C and level and angiographically demonstrated
complex stenosis in patients with ACS and stable angina from
registry of coronary angiography cases. The results of this
study demonstrated that the TN-C levels increased as clinical
severity increased from Stable Angina to ACS and there was
a positive correlation between TN-C expression and the num-
ber of complex lesions in patients with ACS. The present study
differs from Yang et al. study in that the study group only
recent MI patients in the 24 h no intervention done before level
detection and emphasis mainly on TN-C level to predict heart
failure in recent MI.The positive correlation between serum levels of TN-C and
pro-BNP that has been found in the current study can provide
evidence that TN-C can be considered as a biomarker of AMI
which can reﬂect the severity of the condition and predict the
emergence of left ventricular dilatation and heart failure. This
correlation has been also conﬁrmed by Sato et al.20 who
demonstrated the presence of a parallel increase of both
BNP and TN-C in patients with AMI and added that TN-C
could be thus considered as a novel marker for the prediction
of ventricular remodeling and prognosis of AMI.
On the other hand, Nishioka et al.21 discovered that in
patients who respond well to cardiac resynchronization ther-
apy (CRT) as a line of treatment for CHF, the serum levels
of TN-C were signiﬁcantly reduced over 6 months. Similarly,
while angiotensin II induced hypertension in mice and stimu-
lated TN-C expression in ﬁbrotic lesions, treatment with the
aldosterone receptor antagonist eplerenone attenuated ﬁbrosis
and reduced TN-C expression.
Franz et al.22 reported that TN-C, might qualify as promis-
ing novel biomarkers for diagnosis and prognosis of myocar-
dial infarction. BNP has long been considered as a marker
of heart failure and left ventricular remodeling.23
In the current study, a positive correlation between TN-C
level and troponin T level in Group 1 of patients having acute
myocardial infarction was found indicating that circulating
TN-C is generally associated with the severity of left ventricu-
lar dysfunction. This ﬁnding is consistent with the same ﬁnding
reported by Maisel et al.24
In this study, the serum level of TN-C is positively
correlated with the serum level of both CK and CK-MB. This
ﬁnding was not evident in the study of Mayr et al.25 who found
no correlation between TN-C and CK-MB. This may be
attributed to the difference of timing of blood samples. In
our study, samples were taken early coinciding with the peak
level of CK-MB after MI, while in Mayr et al. study, samples
were taken after 5 days of ST-elevated MI.
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